CRVS vs GILD
CRVS: A clinical-stage biopharmaceutical company developing targeted ITK inhibitors to modulate immune function for the treatment of cancer and inflammatory diseases. GILD: A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis, and cancer.
Side-by-side fundamentals
| Metric | CRVS | GILD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $13.99 | $130.34 | |
| Market cap as of 2026-07-23 | $1.2B | $163.6B | |
| P/E as of 2026-07-23 | n/a | 17.75 | |
| PEG as of 2026-07-23 | n/a | 1.94 | |
| Net margin as of 2026-07-23 | n/a | +31.0% | |
| Gross margin as of 2026-07-23 | n/a | +79.3% | |
| Operating margin as of 2026-07-23 | n/a | +34.9% | |
| ROE as of 2026-07-23 | -38.9% | +42.2% | GILD higher |
| ROA as of 2026-07-23 | -35.8% | +16.1% | GILD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.94 | CRVS lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +3.5% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +2.6% | |
| Dividend yield as of 2026-07-23 | n/a | +2.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.93 | 0.34 | |
| 1-year return as of 2026-07-22 close | +225.2% | +18.3% | CRVS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.